Clinical Research Directory
Browse clinical research sites, groups, and studies.
Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease
Sponsor: Eye Surgeons of Indiana
Summary
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in patients with dry eye who are beginning treatment with Xiidra (lifitegrast ophthalmic solution) to reduce the signs and symptoms of dry eye disease.
Official title: Intracanalicular Dexamethasone Used in Conjunction With Xiidra (Lifitegrast Ophthalmic Solution) for the Treatment of Signs and Symptoms of Dry Eye Disease as Compared to Xiidra Alone
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2020-08-01
Completion Date
2022-04-11
Last Updated
2026-10-27
Healthy Volunteers
No
Conditions
Interventions
Lifitegrast 5% Ophthalmic Solution
To reduce signs and symptoms of dry eye disease
Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
Locations (1)
Eye Surgeons of Indiana
Indianapolis, Indiana, United States